{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T23:24:39Z","timestamp":1787181879035,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000015","name":"US Department of Energy","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000015","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.biopha.2026.119736","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T13:46:22Z","timestamp":1784641582000},"page":"119736","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and characterization of [47Sc]Sc-NOTA-trastuzumab for targeted radiotherapy in primary and metastatic HER2\u202f+\u202fbreast cancer"],"prefix":"10.1016","volume":"202","author":[{"given":"Patrick N.","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5578-0342","authenticated-orcid":false,"given":"Shelbie J.","family":"Cingoranelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharmila","family":"Sridhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailey A.","family":"Houson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos A.","family":"Gallegos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-9720-046X","authenticated-orcid":false,"given":"Lily B.","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0137-2397","authenticated-orcid":false,"given":"Jennifer L.","family":"Bartels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Willey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E.","family":"Lapi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna G.","family":"Sorace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119736_bib1","article-title":"Clinical cancer immunotherapy: current progress and prospects","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119736_bib2","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1634\/theoncologist.2010-0035","article-title":"Trastuzumab","volume":"16","author":"Boekhout","year":"2011","journal-title":"Oncologist"},{"issue":"9","key":"10.1016\/j.biopha.2026.119736_bib3","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.2967\/jnumed.108.051771","article-title":"Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate","volume":"49","author":"Costantini","year":"2008","journal-title":"J. Nucl. Med."},{"issue":"5","key":"10.1016\/j.biopha.2026.119736_bib4","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1007\/s11307-024-01948-4","article-title":"Development of (52)Mn labeled trastuzumab for extended time point PET imaging of HER2","volume":"26","author":"Omweri","year":"2024","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.biopha.2026.119736_bib5","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.124.268931","article-title":"Quantitative [(89)Zr]Zr-trastuzumab PET and diffusion- weighted MRI for characterization of metastatic HER2-positive breast cancer with PET\/MRI","author":"Mansur","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"12","key":"10.1016\/j.biopha.2026.119736_bib6","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/RLU.0000000000001820","article-title":"89Zr-Trastuzumab PET\/CT for detection of human epidermal growth factor receptor 2-positive metastases in patients with human epidermal growth factor receptor 2-negative primary breast cancer","volume":"42","author":"Ulaner","year":"2017","journal-title":"Clin. Nucl. Med."},{"issue":"20","key":"10.1016\/j.biopha.2026.119736_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15204980","article-title":"89)Zr-Trastuzumab PET\/CT imaging of HER2-positive breast cancer for predicting pathological complete response after neoadjuvant systemic therapy: a feasibility study","volume":"15","author":"Linders","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.biopha.2026.119736_bib8","first-page":"1018","article-title":"Quantitative [(89)Zr]Zr-trastuzumab PET and diffusion- weighted MRI for characterization of metastatic HER2-positive breast cancer with PET\/MRI","volume":"66","author":"Mansur","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"6","key":"10.1016\/j.biopha.2026.119736_bib9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/CCO.0000000000001087","article-title":"Antibody-drug conjugates in metastatic breast cancer: sequencing, combinations and resistances","volume":"36","author":"Guidi","year":"2024","journal-title":"Curr. Opin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119736_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14041015","article-title":"Modulation of the tumor microenvironment with trastuzumab enables radiosensitization in HER2+ breast cancer","volume":"14","author":"Song","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"16","key":"10.1016\/j.biopha.2026.119736_bib11","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1200\/JCO.2008.17.9549","article-title":"Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831","volume":"27","author":"Halyard","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.biopha.2026.119736_bib12","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1200\/JCO.20.02824","article-title":"Comparison of radiation with or without concurrent trastuzumab for HER2-positive ductal carcinoma in situ resected by lumpectomy: a phase III clinical trial","volume":"39","author":"Cobleigh","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.biopha.2026.119736_bib13","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1001\/jamaoncol.2024.1299","article-title":"Radiation therapy followed by intrathecal trastuzumab-pertuzumab for ERBB2-positive breast leptomeningeal disease: a phase 1 nonrandomized controlled trial","volume":"10","author":"Ahmed","year":"2024","journal-title":"JAMA Oncol."},{"issue":"10","key":"10.1016\/j.biopha.2026.119736_bib14","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1007\/s11912-025-01686-y","article-title":"Prostate cancer radioligand therapy: PSMA and beyond, current landscape and future directions","volume":"27","author":"Bent","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.biopha.2026.119736_bib15","doi-asserted-by":"crossref","DOI":"10.1177\/17588359251409047","article-title":"Current and future perspectives on radioligand therapy in advanced prostate cancer","volume":"18","author":"Ahmed","year":"2026","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"22","key":"10.1016\/j.biopha.2026.119736_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17223717","article-title":"PSMA theranostics in prostate cancer and beyond: current and future perspectives","volume":"17","author":"Sandhu","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.biopha.2026.119736_bib17","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.7150\/thno.107963","article-title":"Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects during (177)Lu\/(225)Ac treatment in neuroendocrine tumors and metastatic prostate cancer","volume":"15","author":"Dadgar","year":"2025","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2026.119736_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102941","article-title":"Current and future directions in theranostics for neuroendocrine prostate cancer","volume":"136","author":"Belge Bilgin","year":"2025","journal-title":"Cancer Treat. Rev."},{"issue":"9","key":"10.1016\/j.biopha.2026.119736_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15092409","article-title":"Radionuclide therapy of HER2-expressing xenografts using [(177)Lu]Lu-ABY-027 affibody molecule alone and in combination with trastuzumab","volume":"15","author":"Liu","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119736_bib20","doi-asserted-by":"crossref","DOI":"10.2967\/jnumed.125.271302","article-title":"Delta-like ligand 3-directed (225)Ac radioimmunotherapy in neuroendocrine lung and prostate cancer models","author":"Hoang","year":"2026","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.biopha.2026.119736_bib21","doi-asserted-by":"crossref","DOI":"10.1007\/s00259-026-07820-7","article-title":"Minimal chemical modification enables alpha\/beta radiolabeling of sacituzumab govitecan for targeted therapy in high grade serous ovarian cancer","author":"Loor","year":"2026","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"10.1016\/j.biopha.2026.119736_bib22","doi-asserted-by":"crossref","first-page":"e236","DOI":"10.1016\/S1470-2045(24)00030-5","article-title":"Recent advances and impending challenges for the radiopharmaceutical sciences in oncology","volume":"25","author":"Lapi","year":"2024","journal-title":"Lancet Oncol."},{"issue":"6","key":"10.1016\/j.biopha.2026.119736_bib23","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nrc3925","article-title":"Radioimmunotherapy of human tumours","volume":"15","author":"Larson","year":"2015","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2026.119736_bib24","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1039\/D0MD00319K","article-title":"Formulation and clinical translation of [(177)Lu]Lu-trastuzumab for radioimmunotheranostics of metastatic breast cancer","volume":"12","author":"Guleria","year":"2021","journal-title":"RSC Med. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2026.119736_bib25","doi-asserted-by":"crossref","first-page":"12871","DOI":"10.1038\/s41598-021-92460-0","article-title":"Combination of (131)I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model","volume":"11","author":"Vinod","year":"2021","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119736_bib26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s41181-023-00208-0","article-title":"[(225)Ac]Ac- and [(111)In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts","volume":"8","author":"Kondo","year":"2023","journal-title":"EJNMMI Radiopharm. Chem."},{"issue":"10","key":"10.1016\/j.biopha.2026.119736_bib27","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.2967\/jnumed.114.143842","article-title":"Dose escalation and dosimetry of first-in-human alpha radioimmunotherapy with 212Pb-TCMC-trastuzumab","volume":"55","author":"Meredith","year":"2014","journal-title":"J. Nucl. Med."},{"issue":"3","key":"10.1016\/j.biopha.2026.119736_bib28","doi-asserted-by":"crossref","DOI":"10.3390\/ph18030295","article-title":"PET imaging expedites detection of aberration in the humanization of an annexin A1 targeting antibody","volume":"18","author":"Houson","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"1","key":"10.1016\/j.biopha.2026.119736_bib29","doi-asserted-by":"crossref","first-page":"11375","DOI":"10.1038\/s41598-025-94923-0","article-title":"PET imaging of differentiated thyroid cancer with thyrotropin-alfa","volume":"15","author":"Gimblet","year":"2025","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.biopha.2026.119736_bib30","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.2967\/jnumed.123.265433","article-title":"Tandem isotope therapy with (225)Ac- and (177)Lu-PSMA-617 in a murine model of prostate cancer","volume":"64","author":"Meyer","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"12","key":"10.1016\/j.biopha.2026.119736_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14122724","article-title":"PET imaging of the neurotensin targeting peptide NOTA-NT-20.3 using cobalt-55, copper-64 and gallium-68","volume":"14","author":"Houson","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119736_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.apradiso.2024.111469","article-title":"Cross section measurements for the production of (49,51)Cr and (47)Sc from proton irradiation of natural vanadium up to 24 MeV","volume":"212","author":"Cingoranelli","year":"2024","journal-title":"Appl. Radiat. Isot."},{"key":"10.1016\/j.biopha.2026.119736_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2023.108872","article-title":"Evaluation of a novel hexadentate 1,2-hydroxypyridinone-based acyclic chelate, HOPO-O(6)-C4, for (43)Sc\/(47)Sc, (68)Ga, and (45)Ti radiopharmaceuticals","volume":"128-129","author":"Carbo-Bague","year":"2024","journal-title":"Nucl. Med. Biol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119736_bib34","doi-asserted-by":"crossref","first-page":"22683","DOI":"10.1038\/s41598-023-49377-7","article-title":"Production and purification of (43)Sc and (47)Sc from enriched [(46)Ti]TiO(2) and [(50)Ti]TiO(2) targets","volume":"13","author":"Cingoranelli","year":"2023","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.biopha.2026.119736_bib35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.2967\/jnumed.117.194555","article-title":"Pharmacokinetics, biodistribution, and radiation dosimetry for (89)Zr-trastuzumab in patients with esophagogastric cancer","volume":"59","author":"O'Donoghue","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119736_bib36","doi-asserted-by":"crossref","first-page":"26","DOI":"10.2967\/jnumed.118.210294","article-title":"Development of (64)Cu-NOTA-Trastuzumab for HER2 targeting: a radiopharmaceutical with improved pharmacokinetics for human studies","volume":"60","author":"Woo","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"1","key":"10.1016\/j.biopha.2026.119736_bib37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s41181-024-00321-8","article-title":"Production of high purity (47)Sc from proton irradiation of natural vanadium targets","volume":"9","author":"Cingoranelli","year":"2024","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.biopha.2026.119736_bib38","series-title":"Mol Pharm","article-title":"Investigating the theranostic potential of elementally matched [(43)Sc]Sc-PSMA-617 and [(47)Sc]Sc-PSMA-617","author":"Cingoranelli","year":"2026"},{"issue":"1","key":"10.1016\/j.biopha.2026.119736_bib39","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0022-1759(84)90435-6","article-title":"Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess","volume":"72","author":"Lindmo","year":"1984","journal-title":"J. Immunol. Methods"},{"issue":"1","key":"10.1016\/j.biopha.2026.119736_bib40","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.1038\/s41598-024-52897-5","article-title":"Dual anti-HER2\/EGFR inhibition synergistically increases therapeutic effects and alters tumor oxygenation in HNSCC","volume":"14","author":"Song","year":"2024","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.biopha.2026.119736_bib41","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.7150\/thno.123588","article-title":"Quantitative dynamic granzyme B PET imaging to characterize novel combination immunotherapy response in preclinical glioblastoma models","volume":"16","author":"Gallegos","year":"2026","journal-title":"Theranostics"},{"issue":"3","key":"10.1016\/j.biopha.2026.119736_bib42","doi-asserted-by":"crossref","first-page":"911","DOI":"10.7150\/thno.89206","article-title":"89)Zr]-CD8 immunoPET imaging of glioblastoma multiforme response to combination oncolytic viral and checkpoint inhibitor immunotherapy reveals CD8 infiltration differential changes in preclinical models","volume":"14","author":"Gallegos","year":"2024","journal-title":"Theranostics"},{"issue":"17","key":"10.1016\/j.biopha.2026.119736_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14174234","article-title":"Quantifying the effects of combination trastuzumab and radiation therapy in human epidermal growth factor receptor 2-positive breast cancer","volume":"14","author":"Bloom","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.biopha.2026.119736_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11082090","article-title":"Combination therapy with trastuzumab and niraparib: quantifying early proliferative alterations in HER2+ breast cancer models","volume":"11","author":"Mansur","year":"2023","journal-title":"Biomedicines"},{"issue":"10","key":"10.1016\/j.biopha.2026.119736_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102708","article-title":"89)Zr]-atezolizumab-PET imaging reveals longitudinal alterations in PDL1 during therapy in TNBC preclinical models","volume":"15","author":"Massicano","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.biopha.2026.119736_bib46","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1021\/acs.molpharmaceut.2c00977","article-title":"Evaluation of a CD206-targeted peptide for PET imaging of macrophages in syngeneic mouse models of cancer","volume":"20","author":"Parker","year":"2023","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119736_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104185","article-title":"Multidisciplinary management of HER2-positive breast cancer with brain metastases: an evidence-based pragmatic approach moving from pathophysiology to clinical data","volume":"192","author":"Giordano","year":"2023","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119736_bib48","doi-asserted-by":"crossref","first-page":"5","DOI":"10.5306\/wjco.v15.i1.5","article-title":"Prognostic factors of breast cancer brain metastasis","volume":"15","author":"Yakar","year":"2024","journal-title":"World J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.biopha.2026.119736_bib49","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101213","article-title":"Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC registry","volume":"8","author":"Riecke","year":"2023","journal-title":"ESMO Open."},{"issue":"8","key":"10.1016\/j.biopha.2026.119736_bib50","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/14740338.2023.2204228","article-title":"High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive\/mutated malignancies: a pharmacovigilance study based on the FAERS database","volume":"22","author":"Ma","year":"2023","journal-title":"Expert. Opin. Drug. Saf."},{"issue":"8","key":"10.1016\/j.biopha.2026.119736_bib51","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cortes","year":"2024","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119736_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041110","article-title":"Lutathera((R)) orphans: state of the art and future application of radioligand therapy with (177)Lu-DOTATATE","volume":"15","author":"Urso","year":"2023","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.biopha.2026.119736_bib53","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.biopha.2026.119736_bib54","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/1754-9485.12891","article-title":"Lu177-PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution","volume":"63","author":"McBean","year":"2019","journal-title":"J. Med. Imaging Radiat. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2026.119736_bib55","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2174\/1874471014999210112205535","article-title":"Accelerator production of scandium radioisotopes: Sc-43, Sc-44, and Sc-47","volume":"14","author":"Chernysheva","year":"2021","journal-title":"Curr. Radiopharm."},{"issue":"8","key":"10.1016\/j.biopha.2026.119736_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11080424","article-title":"Therapeutic potential of (47)Sc in comparison to (177)Lu and (90)Y: preclinical investigations","volume":"11","author":"Siwowska","year":"2019","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.biopha.2026.119736_bib57","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1021\/acs.molpharmaceut.5c01023","article-title":"Investigating the theranostic potential of elementally matched [(43)Sc]Sc-PSMA-617 and [(47)Sc]Sc-PSMA-617","volume":"23","author":"Cingoranelli","year":"2026","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.biopha.2026.119736_bib58","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-021-06447-6","article-title":"Immune cell profiles of metastatic HER2-positive breast cancer patients according to the sites of metastasis","volume":"191","author":"Honkanen","year":"2022","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.biopha.2026.119736_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14061514","article-title":"Radiotherapy for HER 2 positive brain metastases: urgent need for a paradigm shift","volume":"14","author":"Ippolito","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.biopha.2026.119736_bib60","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.annonc.2021.04.011","article-title":"Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE","volume":"32","author":"Mamounas","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2026.119736_bib61","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.breast.2022.10.016","article-title":"Antibody drug conjugates targeting HER2: Clinical development in metastatic breast cancer","volume":"66","author":"Rassy","year":"2022","journal-title":"Breast"},{"issue":"7","key":"10.1016\/j.biopha.2026.119736_bib62","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"602","key":"10.1016\/j.biopha.2026.119736_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb3631","article-title":"Low-dose targeted radionuclide therapy renders immunologically cold tumors responsive to immune checkpoint blockade","volume":"13","author":"Patel","year":"2021","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.biopha.2026.119736_bib64","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005060","article-title":"Antitumor efficacy of (90)Y-NM600 targeted radionuclide therapy and PD-1 blockade is limited by regulatory T cells in murine prostate tumors","volume":"10","author":"Potluri","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2026.119736_bib65","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1563387","article-title":"Immunomodulatory effects of alpha vs beta radiopharmaceutical therapy in murine prostate cancer","volume":"16","author":"Ferreira","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2026.119736_bib66","doi-asserted-by":"crossref","first-page":"12382","DOI":"10.1038\/s41598-023-39372-3","article-title":"Clinicopathological characteristics of HER2-low breast cancer: a retrospective study","volume":"13","author":"Yang","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119736_bib67","first-page":"605","article-title":"HER2-low breast cancer: current landscape and future prospects","volume":"15","author":"Shirman","year":"2023","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.biopha.2026.119736_bib68","article-title":"Low-dose targeted radionuclide therapy synergizes with CAR T cells and enhances tumor response","volume":"15","author":"Yang","year":"2024","journal-title":"Front. Immunol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007729?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332226007729?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T22:46:09Z","timestamp":1787179569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332226007729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":68,"alternative-id":["S0753332226007729"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119736","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and characterization of [47Sc]Sc-NOTA-trastuzumab for targeted radiotherapy in primary and metastatic HER2\u202f+\u202fbreast cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119736","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119736"}}